Herein
is described the development of a large-scale manufacturing
process for molnupiravir, an orally dosed antiviral that was recently
demonstrated to be efficacious for the treatment of patients with
COVID-19. The yield, robustness, and efficiency of each of the five
steps were improved, ultimately culminating in a 1.6-fold improvement
in overall yield and a dramatic increase in the overall throughput
compared to the baseline process.
The Pax6 gene has attracted intense research interest due to its apparently important role in the development of eyes and the central nervous system (CNS) in many animal groups. Pax6 is also of interest for comparative genomics since it has not been duplicated in tetrapods, making for a direct orthology between the Ciona intestinalis gene CiPax6 and Pax6 in mammals. CiPax6 has been shown to be expressed in the anterior brain, caudal nerve cord, and in parts of the brain associated with the photoreceptive ocellus. This information was extended here using in-situ hybridization, and shows that CiPax6 transcripts mark the lateral regions of the nerve cord, remarkably similar to Pax6 expression in the mouse. As a means of dissecting the cis-regulation of CiPax6 we tested 8 kb of sequence using transient reporter transgene assays. Three separate regions were found that work together to drive the overall CiPax6 expression pattern. A 211 bp sequence 2 kb upstream of the first exon was found to be a major enhancer driving expression in the sensory vesicle (the anterior portion of the ascidian brain). Other upstream sequences were shown to work with the sensory vesicle enhancer to drive expression in the remainder of the CNS. An "eye enhancer" was localized to the first intron, which controls specific expression in the central portion of the sensory vesicle, including photoreceptor cells. The fourth intron was found to repress ectopic expression of the reporter gene in middle portions of the embryonic brain. Aspects of this overall regulatory organization are similar to the organization of the Pax6 homologs in mice and Drosophila, particularly the presence of intronic elements driving expression in the eye, brain and nerve cord.
A robust, green, and sustainable
manufacturing process has been
developed for the synthesis of gefapixant citrate, a P2X3 receptor
antagonist that is under investigation for the treatment of refractory
and unexplained chronic cough. The newly developed commercial process
features low process mass intensity (PMI), short synthetic sequence,
high overall yield, minimal environmental impact, and significantly
reduced API costs. The key innovations are the implementation of a
highly efficient two-step methoxyphenol synthesis, an innovative pyrimidine
synthesis in flow, a simplified sulfonamide synthesis, and a novel
salt metathesis approach to consistently deliver the correct active
pharmaceutical ingredient (API) salt form in high purity.
The
manufacturing route toward gefapixant citrate generates a trace
amount of cyanide as a byproduct of a reaction employing the reagent
chloroacetonitrile. In the development of a cyanide control strategy,
conventional process and analytical approaches fell short because
of challenges and incompatibilities with the matrices of the process
and waste streams. To overcome these, we identified and adapted specific
procedures for cyanide control. Our strategy ensured safety for patients,
operators, and waste management.
The development of a safe, robust, and efficient manufacturing route for the synthesis of diaminopyrimidine 1, a key intermediate to gefapixant citrate (MK-7264), is described. A full mechanistic understanding of the cyclization step in the presence of guanidine was established by performing isotopic labeling experiments and identification of impurities. Guided by the mechanistic understanding, further attempts to modify the cyclization reaction by employing additives to reduce the triazine (9) formation and guanidine loading will also be presented. This newly developed method delivered compound 1 in 88−94% yield on a commercial scale and addressed the shortcomings of the early synthetic route including high PMI, low atom economy, long cycle-time, and multiple purifications to achieve the desired quality.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.